Hematology Analyzers
North America · 2 shared keywords
Updated
Reviewed by Chandani Patel
North America Autoimmune Disease Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Product, Disease, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.46 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.46 Bn | — | — |
| 2025 (base) | $2.58 Bn | +$125.3 Mn | — |
| 2026 (forecast) | $2.71 Bn | +$131.7 Mn | +5.1% |
| 2027 (forecast) | $2.85 Bn | +$138.4 Mn | +10.5% |
| 2028 (forecast) | $3.00 Bn | +$145.5 Mn | +16.1% |
| 2029 (forecast) | $3.15 Bn | +$152.9 Mn | +22% |
| 2030 (forecast) | $3.31 Bn | +$160.7 Mn | +28.2% |
| 2031 (forecast) | $3.48 Bn | +$168.9 Mn | +34.8% |
| 2032 (forecast) | $3.66 Bn | +$177.5 Mn | +41.7% |
| 2033 (forecast) | $3.85 Bn | +$186.6 Mn | +48.9% |
| 2034 (forecast) | $4.04 Bn | +$196.1 Mn | +56.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $2.58 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $4.04 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 5.1% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, disease and end user (see all) |
| Key players | Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Werfen, Siemens Healthineers, Euroimmun and 1 more (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Autoimmune disease diagnostics are blood tests that find antibodies and markers to diagnose and track diseases such as lupus and arthritis.
Key segments of the autoimmune disease diagnostics market include product (Immunoassay Kits, Analyzers and Reagents) and disease (Rheumatoid Arthritis, Lupus and Multiple Sclerosis).
Falling costs of testing, more demand for precision medicine and steady research spending by drug makers and labs are driving the autoimmune disease diagnostics market.
Automation, smaller and cheaper instruments and growth in cancer and genetic testing give the autoimmune disease diagnostics market room to grow.
Costly instruments, a shortage of skilled lab staff and uneven payment for new tests hold back the autoimmune disease diagnostics market.
The autoimmune disease diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the countries we cover here, medical devices are regulated by Health Canada (Canada)[1] and FDA (US)[2]. How care is paid for in these countries: provincial health insurance (Canada)[3] and Medicare and Medicaid (US)[4].
[1] Health Canada. Checked 14 Nov 2026.
[2] US Food and Drug Administration. Checked 14 Nov 2026.
[3] Health Canada. Checked 14 Nov 2026.
[4] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how autoimmune disease diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in North America.
From our blog
North America · 2 shared keywords
North America · 1 shared keyword
North America · 1 shared keyword
North America · 1 shared keyword
North America · 1 shared keyword
North America · 1 shared keyword
Digital Health · North America
Healthcare Services · North America
Healthcare Services · North America
Pharmaceuticals · North America
Pharmaceuticals · North America
Healthcare Services · North America